DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA · Military Medical Research and Development (12.420)
Posted 4 May 2026 · Closed 1 day ago
In plain terms
The US Defense Health Agency funds rapid clinical trials to test treatments or improve care for amyotrophic lateral sclerosis, with trials starting within 12 to 18 months of award. Any type of US-based organisation may apply, and the total programme budget is 5.6 million US dollars, but the deadline of 30 September 2026 has passed.
A generated summary of the donor's text; the original wording is below.
Summary
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.
Applications must address one of the following focus areas:
· Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.
· Clinical Care: Improving aspects of clinical care and symptom management for ALS.
Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies.
Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design.
All pre-applications and applications are…
Excerpt from the donor's page. The full text, annexes and forms are on the original call.
Who can apply
- ngo_cso
- academia_research
- private_company
- government
- social_enterprise
- individual
- other
Eligibility and conditions
Show the eligibility text from the source
Applicant types: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"